SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
1-Year Return
17.43%
This Quarter Return
-4.12%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.33B
AUM Growth
-$38.3M
(-2.8%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
8.38%
Top 10 Holdings %
Top 10 Hldgs %
54.83%
Holding
78
New
15
Increased
20
Reduced
13
Closed
16
Top Buys
| 1 |
Stryker
SYK
|
$68M |
| 2 |
Medtronic
MDT
|
$50.6M |
| 3 |
Eli Lilly
LLY
|
$31.7M |
| 4 |
PTC Therapeutics
PTCT
|
$29.5M |
| 5 |
IDEAYA Biosciences
IDYA
|
$25.4M |
Top Sells
| 1 |
AbbVie
ABBV
|
$63.9M |
| 2 |
AstraZeneca
AZN
|
$42.7M |
| 3 |
Gilead Sciences
GILD
|
$39.8M |
| 4 |
Axsome Therapeutics
AXSM
|
$36.9M |
| 5 |
Boston Scientific
BSX
|
$31M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RAPP
26
Rapport Therapeutics
RAPP
$524M
| $20M | 1.31% |
1,995,594
| – | – |
|
27
Supernus Pharmaceuticals
SUPN
$2.58B
| $17.1M | 1.11% |
+520,678
| New | +$17.1M |
|
28
Savara
SVRA
$643M
| $15.2M | 0.99% |
5,481,666
+10,367
| +0.2% | +$28.7K |
|
29
Cogent Biosciences
COGT
$1.82B
| $13.1M | 0.85% |
2,182,121
+1,358,961
| +165% | +$8.14M |
|
30
Roivant Sciences
ROIV
$8.82B
| $12.9M | 0.84% |
+1,279,510
| New | +$12.9M |
|
31
Danaher
DHR
$143B
| $12M | 0.78% |
58,606
+48,606
| +486% | +$9.96M |
|
32
Penumbra
PEN
$11B
| $11.5M | 0.75% |
+42,936
| New | +$11.5M |
|
33
Avidity Biosciences
RNA
$6.48B
| $11.2M | 0.73% |
379,931
+366,142
| +2,655% | +$10.8M |
|
34
Inhibrx
INBX
$408M
| $9.76M | 0.64% |
697,916
+170,726
| +32% | +$2.39M |
|
35
Y-mAbs Therapeutics
YMAB
$390M
| $9.72M | 0.63% |
2,194,278
| – | – |
|
|
JBIO
36
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $9.43M | 0.62% |
107,391
| – | – |
|
37
Pharvaris
PHVS
$1.48B
| $9.32M | 0.61% |
593,403
+32,680
| +6% | +$513K |
|
|
BIOA
38
BioAge Labs, Inc. Common Stock
BIOA
$171M
| $8.67M | 0.57% |
2,304,901
| – | – |
|
39
Arcus Biosciences
RCUS
$1.3B
| $8.15M | 0.53% |
+1,037,776
| New | +$8.15M |
|
40
Edgewise Therapeutics
EWTX
$1.64B
| $7.53M | 0.49% |
342,218
-60,555
| -15% | -$1.33M |
|
41
Dyne Therapeutics
DYN
$2.02B
| $7.5M | 0.49% |
716,896
-354,602
| -33% | -$3.71M |
|
42
Immatics
IMTX
$761M
| $7.01M | 0.46% |
1,554,304
+1,211,098
| +353% | +$5.46M |
|
43
Praxis Precision Medicines
PRAX
$986M
| $5.97M | 0.39% |
+157,640
| New | +$5.97M |
|
44
Intuitive Surgical
ISRG
$167B
| $5.94M | 0.39% |
11,984
-25,912
| -68% | -$12.8M |
|
45
uniQure
QURE
$985M
| $5.79M | 0.38% |
+545,771
| New | +$5.79M |
|
46
Immunome
IMNM
$916M
| $5.31M | 0.35% |
788,666
+41,842
| +6% | +$282K |
|
47
Kura Oncology
KURA
$713M
| $5.23M | 0.34% |
+791,667
| New | +$5.23M |
|
|
INZY
48
DELISTED
Inozyme Pharma
INZY
| $3.9M | 0.25% |
4,280,308
| – | – |
|
49
Scholar Rock
SRRK
$3.02B
| $3.73M | 0.24% |
+116,117
| New | +$3.73M |
|
50
Erasca
ERAS
$457M
| $2.57M | 0.17% |
1,877,085
+81,205
| +5% | +$111K |
|